Search
Now showing items 31-40 of 77
No response or survival improvement in small cell lung cancer after sequential chemotherapy with three non-cross resistant drug regimens - a pilot study
(1991)
In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC ...
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
(1997)
Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
The prognostic evaluation of tumor angiogenesis in invasive breast carcinoma
(2002)
Microvessel density (MVD) was analyzed for associations with clinical and pathological factors as well as with other potential known prognostic factors such as: steroid receptor content (ER, PgR), p53 and proliferation ...
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study
(2004)
We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...
The prognostic value of vascular endothelial growth factor (VEGF) in invasive breast cancer: Correlation with microvessel density (MVD), ER, PgR, p53 and proliferative associated indices (Ki-67, PCNA)
(2002)
The formation of new vessels in both primary tumour and in metastasis induce various growth factors included the vascular endothelial growth factors (VEGF). The immunohistochemical expression of vascular endothelial growth ...
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)
We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
Cancer of unknown primary site: Missing primary or missing biology?
(2007)
Cancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths and represents both a diagnostic and a management challenge. In CUP, the regression or dormancy of the primary tumor, the development ...
A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience
(2002)
Background. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient ...
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
(1998)
The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...